

KE

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Dated: February 8, 2001 Nat'l. Entry From: PCT/NO99/00141				ATTY DOCKET NO. 1702.401600		APPLICATION NO. 09/674,913	
				APPLICANT GUSTAV GAUDERNACK, ET AL.			
				FILING DATE November 8, 2000		GROUP 1647 Unassigned	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT
CDU	—	WO 98/45322	10/1998	WIPO			Yes
CDU	—	WO 97/12992	4/1997	WIPO			Yes
CDU	—	WO 95/32731	12/1995	WIPO			Yes
CDU	—	WO 92/14756	9/1992	WIPO			Yes
CDU	—	WO 99/58552	11/1999	WIPO			Yes

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)		
CDU	—	van Leeuwen et al., (1998, January), Science 279:242-247, "Frameshift Mutants of β Amyloid Precursor Protein and Ubiquitin-B in Alzheimer's and Down Patients"
CDU	—	Vogel, (1998), Science 279:174, "Possible New Cause of Alzheimer's Disease Found"
CDU	—	Gaudernack, (1996), Immunotechnology 2:3-9, "T cell responses against mutant ras: a basis for novel cancer vaccines"
CDU	—	Gjertsen et al. (1996), Int. Journal of Cancer 65:450-453, "Ex Vivo ras Peptide Vaccination in Patients with Advanced Pancreatic Cancer: Results of a Phase I/II Study"
CDU	—	Gjertsen et al. (1997), Int. J. Cancer 72:784-790, "Cytotoxic CD4 ⁺ and CD8 ⁺ T-Lymphocytes, Generated by Mutant p21-ras (12Val) Peptide Vaccination of a Patient, Recognize ... Tumour Cells Carrying This Mutation"
CDU	—	Gjertsen et al. (1998) Vox Sanguinis 74(suppl. 2): 489-495, "Mutated Ras Peptides as Vaccines in Immunotherapy of Cancer"

EXAMINER 	DATE CONSIDERED 11/20/2002
--------------	--------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary) Dated: February 8, 2001 Nat'l. Entry From: PCT/NO99/00141		ATTY DOCKET NO. 1702.401600		APPLICATION NO. 09/674,913	
APPLICANT GUSTAV GAUDERNACK, ET AL.		FILING DATE Nov mber 8, 2000		GROUP 16A Unassigned	

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT		

OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)	
CDN	Terry et al., Alzheimer Disease, 1994, pp. 179-196, "Structural Basis of the Cognitiv Alterations in Alzheimer Disease".
CDN	Barinaga, Science, vol. 257, 1992, pp. 880-881, "Getting Some 'Backbone': How MHC Binds Peptides".
CDN	Deres et al., Nature, vol. 342, 1989, pp. 561-564, "In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine".
CDN	Tighe et al., Immun. Today, vol. 19(2), 1998, pp. 89-97, "Gene vaccination: plasmid DNA is more than just a blueprint".

EXAMINER 	DATE CONSIDERED 11/20/2002
--------------	--------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 2 of 2